Phaseline

Companies › HanAll BioPharma

HanAll BioPharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Other; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Leuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4CPPNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06926933LeuprolidePhase 4CPPOtherNov 2027

Targets

GNRHR (1)

Companies with the same targets

LG Chem JW Pharmaceutical Amgen AbbVie Pfizer TerSera Therapeutics Qilu Pharmaceutical Zhuhai Huahaikang Pharmaceutical Technology Kissei Pharmaceutical Changchun GeneScience Pharmaceutical

Companies built like this

Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.